Literature DB >> 618707

Determination of procainamide acetylator status.

J J Lima, W J Jusko.   

Abstract

Variation in renal function can obscure the measurement of acetylator status for compounds such as procainamide in which appreciable active drug or acetyl metabolite is excreted in urine. Computer simulations and patient studies were used to compare two common metabolite/drug ratio methods and a proposed clearance technique for phenotyping acetylation rate. The calculation of apparent acetylation clearance from steady-state serum concentrations of procainamide and urinary excretion rates of N-acetyl-procainamide provides the most definitive discrimination between fast and slow acetylators.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 618707     DOI: 10.1002/cpt197823125

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Pharmacokinetics of sulphamethoxazole in man: effects of urinary pH and urine flow on metabolism and renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole.

Authors:  T B Vree; Y A Hekster; A M Baars; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

Review 2.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

3.  Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances.

Authors:  Larry A Bauer; Douglas J Black; Jennifer S Lill; Julie Garrison; Vidmantas A Raisys; Thomas M Hooton
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 4.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

5.  Pharmacokinetics of N1-acetyl- and N4-acetylsulphamethoxazole in man.

Authors:  T B Vree; Y A Hekster; J E Damsma; E van der Kleijn; W J O'Reilly
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

6.  Metabolism of procainamide in patients with chronic heart failure, chronic respiratory failure and chronic renal failure.

Authors:  P du Souich; S Erill
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

7.  The pharmacokinetics of slow-release procainamide.

Authors:  W J Tilstone; D H Lawson; W Campbell; I Hutton; T D Lawrie
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

8.  Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Authors:  J J Lima; D R Conti; A L Goldfarb; W J Tilstone; L H Golden; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

9.  Pharmacokinetic approach to intravenous procainamide therapy.

Authors:  J J Lima; D R Conti; A L Goldfarb; L H Golden; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of N-acetylprocainamide.

Authors:  S J Connolly; R E Kates
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.